Phase Ib Study Evaluating the c-Met Inhibitor INC280 in Combination With Bevacizumab in Patients With Glioblastoma Multiforme (GBM)

Trial Profile

Phase Ib Study Evaluating the c-Met Inhibitor INC280 in Combination With Bevacizumab in Patients With Glioblastoma Multiforme (GBM)

Recruiting
Phase of Trial: Phase I

Latest Information Update: 19 May 2017

At a glance

  • Drugs Capmatinib (Primary) ; Bevacizumab
  • Indications Colorectal cancer; Glioblastoma; Gliosarcoma; Renal cell carcinoma
  • Focus Adverse reactions
  • Sponsors SCRI Development Innovations
  • Most Recent Events

    • 11 May 2017 Planned End Date changed from 1 May 2018 to 1 Nov 2019.
    • 11 May 2017 Planned primary completion date changed from 1 Nov 2017 to 1 Sep 2018.
    • 24 Jul 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top